Societe Generale Reaffirms “Buy” Rating for AstraZeneca plc (AZN)

AstraZeneca plc (LON:AZN)‘s stock had its “buy” rating reissued by equities research analysts at Societe Generale in a research note issued on Thursday.

A number of other equities analysts have also recently issued reports on AZN. HSBC Holdings plc restated a “hold” rating and set a GBX 4,700 ($59.07) price target on shares of AstraZeneca plc in a report on Wednesday, November 23rd. JPMorgan Chase & Co. cut their price target on AstraZeneca plc from GBX 4,900 ($61.58) to GBX 4,600 ($57.81) and set a “neutral” rating on the stock in a report on Monday, November 28th. Deutsche Bank AG restated a “buy” rating and set a GBX 6,000 ($75.41) price target on shares of AstraZeneca plc in a report on Wednesday, November 30th. Berenberg Bank restated a “buy” rating and set a GBX 5,500 ($69.12) price target on shares of AstraZeneca plc in a report on Tuesday, December 6th. Finally, Liberum Capital restated a “hold” rating and set a GBX 5,200 ($65.35) price target on shares of AstraZeneca plc in a report on Thursday, December 8th. Four equities research analysts have rated the stock with a sell rating, six have given a hold rating, eleven have assigned a buy rating and one has given a strong buy rating to the company. The company presently has an average rating of “Hold” and a consensus price target of GBX 5,079.90 ($63.84).

Analyst Recommendations for AstraZeneca plc (LON:AZN)

Shares of AstraZeneca plc (LON:AZN) traded up 0.93% during trading on Thursday, reaching GBX 4974.50. 2,043,529 shares of the company were exchanged. AstraZeneca plc has a one year low of GBX 3,680.00 and a one year high of GBX 5,505.00. The firm’s 50 day moving average price is GBX 4,706.64 and its 200 day moving average price is GBX 4,603.53. The company’s market capitalization is GBX 62.94 billion.

The firm also recently announced a dividend, which was paid on Monday, March 20th. Stockholders of record on Thursday, February 16th were given a dividend of GBX 150.20 ($1.89) per share. The ex-dividend date of this dividend was Thursday, February 16th. This is a positive change from AstraZeneca plc’s previous dividend of $68.70. This represents a dividend yield of 3.52%.

COPYRIGHT VIOLATION NOTICE: “Societe Generale Reaffirms “Buy” Rating for AstraZeneca plc (AZN)” was originally reported by Mideast Time and is the property of of Mideast Time. If you are viewing this story on another site, it was stolen and republished in violation of international copyright and trademark law. The legal version of this story can be viewed at https://www.mideasttime.com/astrazeneca-plc-azn-stock-rating-reaffirmed-by-societe-generale/1588598.html.

AstraZeneca plc Company Profile

AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on discovery and development of products, which are then manufactured, marketed and sold. The Company focuses on three main therapy areas: Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience.

Receive News & Ratings for AstraZeneca plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca plc and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply

 
© 2006-2017 Mideast Time.